Day One Biopharmaceuticals Stock Performance
| DAWN Stock | USD 11.95 0.39 3.16% |
On a scale of 0 to 100, Day One holds a performance score of 11. The firm shows a Beta (market volatility) of -0.38, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Day One are expected to decrease at a much lower rate. During the bear market, Day One is likely to outperform the market. Please check Day One's downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to make a quick decision on whether Day One's price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Day One Biopharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Day One displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 230.8 M | |
| Total Cashflows From Investing Activities | -231 M |
Day One Relative Risk vs. Return Landscape
If you would invest 750.00 in Day One Biopharmaceuticals on October 27, 2025 and sell it today you would earn a total of 445.00 from holding Day One Biopharmaceuticals or generate 59.33% return on investment over 90 days. Day One Biopharmaceuticals is currently generating 0.969% in daily expected returns and assumes 6.8741% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than Day, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Day One Target Price Odds to finish over Current Price
The tendency of Day Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 11.95 | 90 days | 11.95 | about 1.4 |
Based on a normal probability distribution, the odds of Day One to move above the current price in 90 days from now is about 1.4 (This Day One Biopharmaceuticals probability density function shows the probability of Day Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Day One Biopharmaceuticals has a beta of -0.38 suggesting as returns on the benchmark increase, returns on holding Day One are expected to decrease at a much lower rate. During a bear market, however, Day One Biopharmaceuticals is likely to outperform the market. Additionally Day One Biopharmaceuticals has an alpha of 0.9852, implying that it can generate a 0.99 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Day One Price Density |
| Price |
Predictive Modules for Day One
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Day One Biopharmaceu. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Day One's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Day One Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Day One is not an exception. The market had few large corrections towards the Day One's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Day One Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Day One within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.99 | |
β | Beta against Dow Jones | -0.38 | |
σ | Overall volatility | 1.26 | |
Ir | Information ratio | 0.13 |
Day One Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Day One for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Day One Biopharmaceu can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Day One Biopharmaceu is way too risky over 90 days horizon | |
| Day One Biopharmaceu appears to be risky and price may revert if volatility continues | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 131.16 M. Net Loss for the year was (95.5 M) with profit before overhead, payroll, taxes, and interest of 119.56 M. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (78.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Over 85.0% of the company shares are held by institutions such as insurance companies |
Day One Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Day Stock often depends not only on the future outlook of the current and potential Day One's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Day One's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 93.6 M | |
| Cash And Short Term Investments | 531.7 M |
Day One Fundamentals Growth
Day Stock prices reflect investors' perceptions of the future prospects and financial health of Day One, and Day One fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Day Stock performance.
| Return On Equity | -0.3 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 778.29 M | |||
| Shares Outstanding | 102.68 M | |||
| Price To Earning | 3.88 X | |||
| Price To Book | 2.72 X | |||
| Price To Sales | 9.18 X | |||
| Revenue | 131.16 M | |||
| EBITDA | (86.32 M) | |||
| Cash And Equivalents | 394.86 M | |||
| Cash Per Share | 5.38 X | |||
| Total Debt | 2.6 M | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 4.39 X | |||
| Cash Flow From Operations | (78.11 M) | |||
| Earnings Per Share | (1.52) X | |||
| Total Asset | 582.79 M | |||
| Retained Earnings | (554.08 M) | |||
About Day One Performance
By examining Day One's fundamental ratios, stakeholders can obtain critical insights into Day One's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Day One is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Day One operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people.Things to note about Day One Biopharmaceu performance evaluation
Checking the ongoing alerts about Day One for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Day One Biopharmaceu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Day One Biopharmaceu is way too risky over 90 days horizon | |
| Day One Biopharmaceu appears to be risky and price may revert if volatility continues | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 131.16 M. Net Loss for the year was (95.5 M) with profit before overhead, payroll, taxes, and interest of 119.56 M. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (78.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Over 85.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Day One's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Day One's stock is overvalued or undervalued compared to its peers.
- Examining Day One's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Day One's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Day One's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Day One's stock. These opinions can provide insight into Day One's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.